Nuclear Pharmacy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Institutional and Commercial), By Purpose (Diagnostic and Therapeutic), By Region and Competition, 2020-2030F

Market Overview

The Global Nuclear Pharmacy Market, valued at USD 5.99 Billion in 2024, is projected to experience a CAGR of 7.92% to reach USD 9.46 Billion by 2030. Nuclear pharmacy involves the preparation and dispensing of radioactive materials for patient administration in nuclear medicine, utilizing radiopharmaceuticals for diagnostic and therapeutic purposes. Market growth is driven by the increasing prevalence of chronic diseases like cancer and cardiovascular disorders, advancements in nuclear medicine technologies, and a growing demand for personalized medicine, expanding applications across oncology and neurology.

According to the International Atomic Energy Agency (IAEA), between 2023 and April 2024, approximately 48,000 targeted radionuclide therapies with Lutetium-177 PSMA were performed annually in 32 countries, and around 43,000 Lutetium-177 DOTATATE therapies were conducted yearly in 39 countries. A significant challenge impeding market expansion stems from persistent supply chain disruptions and shortages of critical radioisotopes, further complicated by their inherently short half-lives requiring complex logistics.

Key Market Drivers

The global nuclear pharmacy market is significantly influenced by two major driving factors: the rising burden of chronic diseases and continuous advancements in radiopharmaceutical development. The increasing global burden of chronic diseases represents a primary impetus for the nuclear pharmacy market, necessitating sophisticated diagnostic and therapeutic interventions. Conditions like cancer, cardiovascular disorders, and neurodegenerative diseases exhibit growing prevalence worldwide, driving escalating demand for early, accurate detection and targeted treatment. Nuclear medicine, offering functional and molecular imaging, proves crucial in disease staging, treatment monitoring, and personalized therapy selection. According to the American Cancer Society, in January 2024, their annual Cancer Statistics report revealed new cancer diagnoses in the United States reached over 2 million (2,001,140) for the first time, underscoring the persistent need for radiopharmaceuticals. This demand for advanced agents is further evidenced by the European Association of Nuclear Medicine (EANM) annual congress in October 2024, which attracted over 8,680 participants, its largest attendance to date.

Simultaneously, continuous advancements in radiopharmaceutical development significantly broaden nuclear medicine's therapeutic and diagnostic scope. Innovations in radionuclide production, chelator chemistry, and targeting mechanisms create novel agents with improved specificity, efficacy, and safety. This includes theranostic agents, integrating diagnostic imaging with targeted radionuclide therapy for personalized patient management. Such progress enhances existing applications and opens new avenues for nuclear medicine, expanding the market. For instance, according to a February 2025 review article in Seminars in Nuclear Medicine, 34 active phase 3 clinical trials are underway for therapeutic radiopharmaceuticals, evaluating new agents or expanding indications. These intensive research and development efforts directly contribute to market expansion by introducing advanced nuclear medicine solutions for complex medical needs.

Download Free Sample Report

Key Market Challenges

A significant challenge impeding the Global Nuclear Pharmacy Market's growth is the persistent supply chain disruptions and shortages of critical radioisotopes. The inherently short half-lives of these materials, such as Technetium-99m, necessitate complex and highly efficient logistics, making the supply chain exceptionally vulnerable to any interruption in production or distribution. This reliance on a limited number of aging nuclear reactors for isotope generation, coupled with unpredictable maintenance schedules or unexpected outages, frequently leads to insufficient supply.

These disruptions directly hamper market expansion by limiting the availability of essential radiopharmaceuticals for both diagnostic imaging and therapeutic procedures. When supply is constrained, nuclear pharmacies face difficulties in meeting patient demand, potentially leading to delayed or cancelled medical scans and treatments. For instance, according to Nuclear Medicine Europe, an industry association, shortages of Molybdenum-99 (Mo-99) to Technetium-99m (Tc-99m) generator manufacturers were anticipated to be as high as 40% in late 2024 due to reactor issues. Such substantial shortfalls directly restrict the volume of procedures that can be performed, impeding revenue growth and delaying crucial patient care across various medical applications.

Key Market Trends

The emergence of targeted alpha therapies significantly influences the global nuclear pharmacy market by introducing a potent and precise cancer treatment modality. These therapies deliver highly localized radiation using alpha-emitting isotopes, effectively targeting malignant cells with minimal damage to healthy tissues, thus expanding therapeutic options. In January 2025, a Society of Nuclear Medicine and Molecular Imaging (SNMMI) strategy meeting indicated two-thirds of physicians anticipated over 10% growth in therapy at their facilities within the year. This is reinforced by Sanofi's AlphaMedix (Lead-212-DOTAMTATE) receiving FDA Breakthrough Therapy Designation in February 2024, followed by positive Phase 2 results for gastroenteropancreatic neuroendocrine tumors in October 2025.

The increasing integration of artificial intelligence (AI) in radiopharmaceutical development is a transformative trend, streamlining discovery and clinical phases. AI algorithms enhance target identification, molecular design, and trial optimization, reducing development timelines and costs. Recognizing this impact, the European Radiation Dosimetry Group (EURADOS) established a pilot group in September 2023 to guide AI's "application in the quickly developed nuclear medicine field," demonstrating an industrial association's commitment to AI in radiopharmaceutical therapy dosimetry and research. Furthermore, the Society of Nuclear Medicine and Molecular Imaging (SNMMI) launched its AI-powered "Global Radiopharmaceutical Trial Finder" in August 2025, accelerating patient and researcher access to clinical trials.

Segmental Insights

The Institutional segment is experiencing rapid growth within the Global Nuclear Pharmacy Market due to its fundamental role in addressing the increasing prevalence of chronic diseases. Hospitals and various healthcare facilities are primary centers for a wide array of nuclear medicine procedures, particularly for conditions like cancer and cardiovascular disorders, driving consistent demand for radiopharmaceuticals. These institutions benefit from established infrastructure, advanced imaging technologies, and a concentration of skilled professionals essential for both diagnostic and therapeutic applications. Furthermore, supportive regulatory environments, overseen by bodies such as the Food and Drug Administration, ensure the safety and efficacy of new radiopharmaceuticals, further propelling institutional adoption and expansion.

Regional Insights

North America leads the global nuclear pharmacy market due to its advanced healthcare infrastructure and robust research and development investments. The region benefits from a high adoption rate of innovative diagnostic and therapeutic radiopharmaceuticals, driven by the increasing prevalence of chronic diseases like cancer. Strong regulatory frameworks, including the oversight by the U. S. Food and Drug Administration (FDA) and the Canadian Nuclear Safety Commission (CNSC), ensure product safety and efficacy, fostering market confidence and encouraging technological advancements. Furthermore, the presence of key market players and supportive reimbursement policies contribute significantly to North America's dominant position.

Recent Developments

• In January 2025, Curium announced an expanded partnership with Institute of Isotopes Co. Ltd. (Izotop) to increase the availability of Iodine-131 diagnostic capsules in Europe. This agreement allows Curium to offer Iodine-131 solutions for both diagnostic and therapeutic applications, particularly addressing concerns regarding the contracting supply of Iodine-131 products across the European nuclear medicine industry. This expansion follows Curium's 2024 investments in its Petten production facilities, including additional manufacturing shifts and automation, to bolster the continuous supply of this essential medical isotope.

• In October 2024, Curium, a leader in nuclear medicine, announced a strategic partnership with PDRadiopharma Inc. for the clinical development, regulatory filing, and commercialization of ¹⁷⁷Lu-PSMA-I&T and ⁶⁴Cu-PSMA-I&T in Japan. This collaboration aims to accelerate the introduction of innovative products for prostate cancer treatment and diagnostics by leveraging both companies' strengths. PDRadiopharma will lead local regulatory, manufacturing, and distribution activities, while Curium continues to lead global development and supports technology transfer for high-throughput copper-64 manufacturing.

• In October 2024, NorthStar Medical Radioisotopes, a global innovator in radiopharmaceuticals, unveiled its new Dose Manufacturing Center in Beloit, Wisconsin. This 52,000 square-foot Contract Development & Manufacturing (CDMO) facility was designed to significantly enhance the development and production of diagnostic and therapeutic radiopharmaceuticals. The center will provide dose manufacturing capacity for key medical radioisotopes, including actinium-225, lutetium-177, copper-64, copper-67, and indium-111, aiming to support biopharmaceutical companies with customized solutions for radiopharmaceutical manufacturing complexities and meet growing industry demands.

• In October 2024, ITM Isotope Technologies Munich SE (ITM), a radiopharmaceutical biotech company, along with the Technical University of Munich (TUM) and the TUM University Hospital, signed a new framework agreement. This expanded collaboration focuses on the research and development of innovative radiopharmaceuticals and radionuclides for cancer treatment. The agreement integrates ITM's expertise in medical radioisotope production with TUM's research capabilities in nuclear physics and medical applications, alongside the TUM University Hospital's clinical expertise. This initiative aims to accelerate advancements in nuclear medicine for targeted cancer therapies.

Key Market Players

• Jubilant Radiopharma (Jubilant Pharma Holdings Inc.)
• GE HealthCare Technologies, Inc.
• Cardinal Health, Inc.
• ARTMS Inc.
• AnazaoHealth Corp.
• Sofie Biosciences, Inc.
• Pacific Radiopharmacy, Ltd.
• NTP Radioisotopes SOC Ltd.
• Lantheus Medical Imaging, Inc.
• ANSTO Nuclear Medicine Pty Ltd.

Report Scope:

In this report, the Global Nuclear Pharmacy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Nuclear Pharmacy Market, By Type:

o   Institutional

o   Commercial

• Nuclear Pharmacy Market, By Purpose:

o   Diagnostic

o   Therapeutic

• Nuclear Pharmacy Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Nuclear Pharmacy Market.

Available Customizations:

Global Nuclear Pharmacy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Nuclear Pharmacy Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]